What is the first line treatment for Latent Tuberculosis?

The first-line treatment for latent tuberculosis (LTBI) includes several options, reflecting current clinical guidelines that aim to effectively prevent the progression to active tuberculosis disease. The selection of such treatments is crucial to ensure a high rate of cure while minimizing side effects.

Isoniazid for 9 months, Rifampin for 4 months, and the combination of Isoniazid + Rifapentine for 3 months are current recommendations. Each of these regimens has been studied and validated for effectiveness in treating LTBI. Isoniazid has a long history of use and is considered effective, while Rifampin offers a shorter duration of treatment, which can enhance patient compliance. The option of combining Isoniazid with Rifapentine (given weekly) presents an alternative regimen, which is more convenient and may improve adherence.

The key aspect of these treatment options is that they effectively reduce the risk of developing active tuberculosis, which is essential for public health and individual patient care. By having varied options for treatment duration and regimen, healthcare providers can tailor the approach based on patient preferences, medical history, and potential drug interactions.

The other treatments mentioned, such as RIPE therapy, which includes Rifampicin, Isoniazid, Pyrazinam